Citations

1. Beers MH, et al., eds. (2004). Merck Manual of Health and Aging. Whitehouse Station, NJ: Merck Research Laboratories.

2. Drugs for cognitive loss and dementia (2007). Treatment Guidelines From The Medical Letter, 5(54): 9–14.

3. Verghese J, et al. (2003). Low blood pressure and the risk of dementia in very old individuals. Neurology, 61(12): 1667–1672.

4. Garcia A, Zanibbi K (2004). Homocysteine and cognitive function in elderly people. Canadian Medical Association Journal, 171(8): 897–904.

5. Shumaker SA, et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative memory study: A randomized controlled trial. JAMA, 289(20): 2651–2662.

6. Espeland MA, et al. (2004). Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA, 291(24): 2959–2968.

7. North American Menopause Society (2004). Abridged recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause Management, 13(6): 12–19. Also available online: http://www.menopausemgmt.com/issues/13-06/issue.html.

8. Mathuranath PS, et al. (2000). A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 55(11): 1613–1620.

9. Knopman DS, et al. (2001). Practice parameter: Diagnosis of dementia (an evidence-based review). Neurology, 56(9): 1143–1153.

10. Wilkinson D, et al. (2003). Donepezil in vascular dementia. Neurology, 61(4): 479–486.

11. Malouf R, Birks J (2006). Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews (4). Oxford: Update Software.

12. Warner J, et al. (2006). Dementia, search date February 2006. Online version of Clinical Evidence (15): 1–24.

13. McShane R, et al. (2006). Memantine for dementia. Cochrane Database of Systematic Reviews (4). Oxford: Update Software.

14. Bird TD, Miller BL (2005). Alzheimer's disease and other dementias. Harrison's Principles of Internal Medicine, 16th ed., pp. 2393–2406. New York: McGraw-Hill.

15. U.S. Food and Drug Administration (2005). FDA issues public health advisory for antipsychotic drugs used for treatment of behavioral disorders in elderly patients. FDA Talk Paper T05-13. Available online: http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01350.html.

16. Wang PS, et al. (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. NEJM, 353(22): 2335–2341.

17. U.S. Department of Health and Human Services (2008). 2008 Physical Activity Guidelines for Americans (ODPHP Publication No. U0036). Washington, DC: U.S. Government Printing Office. Available online: http://www.health.gov/paguidelines/pdf/paguide.pdf.

18. Roman GC (2002). Vascular dementia revisited: Diagnosis, pathogenesis, treatment, and prevention. Medical Clinics of North America, 86(3): 477–499.

19. Verghese J, et al. (2003). Leisure activities and the risk of dementia in the elderly. New England Journal of Medicine, 348(25): 2508–2516.

20. Mukamal KJ, et al. (2003). Prospective study of alcohol consumption and risk of dementia in older adults. JAMA, 289(11): 1405–1413.

21. Ruitenberg A, et al. (2002). Alcohol consumption and risk of dementia: The Rotterdam study. Lancet, 359(9303): 281–286.

22. Jick H, et al. (2000). Statins and the risk of dementia. Lancet, 356(9242): 1627–1631.

23. Zandi PP, et al. (2005). Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County study. Archives of General Psychiatry, 62(2): 217–224.

24. Li G, et al. (2004). Statin therapy and risk of dementia in the elderly. Neurology, 63(9): 1624–1628.

25. Tzourio C, et al. (2003). Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Archives of Internal Medicine, 163(9): 1069–1075.

26. Richards JB, et al. (2007). Effect of selective serotonin reuptake inhibitors on the risk of fracture. Archives of Internal Medicine, 167(2): 188–194.

27. Spector A, et al. (2003). Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia. British Journal of Psychiatry, 183: 248–254.

28. Graff MJ, et al. (2006). Community-based occupational therapy for patients with dementia and their caregivers: Randomised controlled trial. BMJ, 333(1196). Also available online: http://www.bmj.com/cgi/content/full/333/7580/1196.

Other Works Consulted

• Kennedy GJ (2003). Dementia. In CK Cassel et al., eds., Geriatric Medicine, 4th ed., pp. 1079–1093. New York: Springer-Verlag.

• Kertesz A, Munoz DG (2002). Frontotemporal dementia. Medical Clinics of North America, 86(3): 501–518.

• Knopman DS (2006). Alzheimer disease and other major dementing illnesses. In DC Dale, DD Federman, eds., ACP Medicine, section 11, chap. 11. New York: WebMD.

• Knopman DS, et al. (2003). Symposium on geriatrics: Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clinic Proceedings, 78(10): 1290–1308.

• Langa KM, et al. (2004). Mixed dementia: Emerging concepts and therapeutic implications. JAMA, 292(23): 2901–2908.

• Leverenz JB, McKeith IG (2002). Dementia with Lewy bodies. Medical Clinics of North America, 86(3): 519–535.

• Santacruz KS, Swagerty D (2001). Early diagnosis of dementia. American Family Physician, 63(4): 703–713.

• U.S. Preventive Services Task Force (2003). Screening for dementia: Recommendation and rationale. Annals of Internal Medicine, 139(11): 925–926.

• Weiner MF, Lipton AM, eds. (2003). The Dementias: Diagnosis, Treatment, and Research, 3rd ed. Washington, DC: American Psychiatric Publishing.